ALYSSA SKALITZKY: Open Payments
NPI 1598906596 · KENOSHA, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,477 in 151 payments from 19 companies in 2025. Trend: 2023 $1,423 · 2024 $1,206 · 2025 $2,477
Food & beverage: $2,369Education: $108
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 16 | $330 |
| Teva Pharmaceuticals USA, Inc. | 12 | $279 |
| Neurocrine BioSciences, Inc. | 15 | $252 |
| Axsome Therapeutics, Inc. | 20 | $229 |
| Supernus Pharmaceuticals, Inc. | 18 | $228 |
| Otsuka America Pharmaceutical, Inc. | 12 | $222 |
| Vanda Pharmaceuticals Inc. | 11 | $179 |
| Janssen Pharmaceuticals, Inc | 13 | $168 |
| ABBVIE INC. | 12 | $159 |
| Lundbeck LLC | 4 | $87 |
Products named: ARISTADA, INGREZZA, Auvelity, Qelbree, REXULTI, FANAPT, AUSTEDO XR, VRAYLAR.
Industry payments across WI — which companies pay providers there.
